# US 2008/0306164 A1 · New 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17beta-hydroxy steroid dehydrogenase type 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306164 A1
- Document ID: US20080306164A1
- Status: Published application
- Kind: A1
- Application number: 12/192,446
- Filed: 2008-08-15
- Published: 2008-12-11
- Earliest claimed: 2004-07-02
- Assignees: Bayer Schering Pharma Aktiengesellschaft
- Inventors: Alexander Hillisch; Olaf Peters; Christian Gege; Wilko Regenhardt; Gabriele Moeller; Dominga Deluca; Jerzy Adamski; Walter Elger; Birgitt Schneider
- Web page: https://patentgrep.com/patent/US20080306164A1

## CPC

- C07J 63/00: Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C8-alkyloxy group or a halogen atom, R13 means a hydrogen atom or a methyl group, R17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17β-hydroxy steroid dehydro-genase type 1.

## Claims

### Claim at position 1

-14. (canceled)

### Claim 15

A 2-substituted D-homo-estratriene compound of formula I
in which
R2 means a C2-C8-alkenyl group, a C1-C8-alkyloxy group or a halogen atom,
R13 means a hydrogen atom or a methyl group,
R17 means a hydrogen atom or a fluorine atom,
whereby the dotted lines in each of the B- and D-ring of the steroid molecule mean optional additional double bonds,
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

A 2-substituted D-homo-estratriene compound according to claim 15, wherein R13 is a hydrogen atom.

### Claim 17 (depends on 15)

A 2-substituted D-homo-estratriene compound according to claim 15, which is:
1) 2-Methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
2) 2-Ethoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
3) 2-Chloro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
4) 2-Bromo-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
5) 2-Iodo-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
6) 2-Chloro-17α-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
7) 2-Chloro-17β-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
8) 2-Bromo-17α-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
9) 2-Bromo-17β-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
10) 2-Allyl-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
11) 2-Allyl-17α-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
12) 2-Allyl-17β-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
13) 2-Chloro-17a-oxo-17a-homoestra-1,3,5(10),16-tetraen-3-ol;
14) 2-Bromo-17a-oxo-17a-homoestra-1,3,5(10),16-tetraen-3-ol;
15) 2-Allyl-17a-oxo-17a-homoestra-1,3,5(10),16-tetraen-3-ol;
16) 2-Propyl-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol;
17) 2-Methoxy-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
18) 2-Ethoxy-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
19) 2-Chloro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
20) 2-Bromo-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
21) 2-Iodo-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
22) 2-Chloro-17α-Fluoro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
23) 2-Chloro-17β-Fluoro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
24) 2-Bromo-17α-Fluoro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
25) 2-Bromo-17β-Fluoro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
26) 2-Allyl-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
27) 2-Allyl-17α-Fluoro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
28) 2-Allyl-17β-Fluoro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol;
29) 2-Chloro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10),16-tetraen-3-ol;
30) 2-Bromo-17a-oxo-17a-homo-18a-homoestra-1,3,5(10),16-tetraen-3-ol; or
31) 2-Allyl-17a-oxo-17a-homo-18a-homoestra-1,3,5(10),16-tetraen-3-ol.

### Claim 18 (depends on 15)

A pharmaceutical composition that comprises at least one compound of formula I according to claim 15 and a pharmaceutically compatible adjuvant and/or vehicle.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the composition further comprises at least one additional active ingredient.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the at least one additional active ingredient is an antiandrogen, antigestagen, aromatase inhibitor or an antiestrogen.

### Claim 21 (depends on 18)

The pharmaceutical composition of claim 18, wherein the composition is provided in a daily dose form containing 5 μg to 50 mg, per kg body weight of the intended patient, of the at least one compound of formula I.

### Claim 22 (depends on 15)

A method for preparing a medicament which comprises at least one compound of formula I according to claim 15, wherein the method comprises formulating at least one compound of formula I into a suitable medicament form.

### Claim 23 (depends on 15)

A method for treating an estrogen-dependent disease that can be positively influenced by the inhibition of the 17β-hydroxy steroid dehydrogenase wherein the disease is selected from breast cancer, prostate cancer and endometriosis, which comprises administering to a patient in need thereof a 17β-hydroxy steroid dehydrogenase inhibiting effective amount of a 2-substituted D-homoestra-1,3,5(10)-triene compound according to claim 15.

### Claim 24 (depends on 23)

The method of claim 23, wherein the at least one compound of formula I is administered in a daily dose of 5 μg to 50 mg per kg of body weight of the patient.

### Claim 25 (depends on 23)

The method of claim 23, wherein the at least one compound of formula I is administered in a daily dose of 10 μg to 30 mg per kg of body weight of the patient.

### Claim 26 (depends on 23)

The method of claim 23, which further comprises administering to the patient at least one additional active ingredient.

### Claim 27 (depends on 26)

The method of claim 26, wherein the at least one additional active ingredient is an antiandrogen, antigestagen, aromatase inhibitor or an antiestrogen.
